Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Autoimmune Disorders

Free Subscription 16.02.2026 2 Ann Neurol 3 BMC Neurol 2 Brain 1 Curr Opin Immunol 12 Diabet Med 1 Diabetes 4 Intern Med 1 J Autoimmun 2 J Clin Endocrinol Metab 4 J Neuroimmunol 8 J Neurol 3 J Rheumatol 1 Lancet 2 Mult Scler 1 N Engl J Med 3 Neurology 2 PLoS One 2 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. LOREFICE L, Pellecchia MT
   Frailty across Neurological Diseases: Why Sex and Gender Matter.
   Ann Neurol. 2025 Nov 21. doi: 10.1002/ana.78110.
   PubMed         Abstract available
   
   
2. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".
   Ann Neurol. 2026;99:553.
   PubMed        
   
   

   
   BMC Neurol

3. GHEZELHESARI EM, Tehrani MV, Nahayati M, Ebrahimipour H, et al
   A systematic review of consensus recommendations and guidelines on the management and care of women with multiple sclerosis through pre-pregnancy, pregnancy, and postpartum periods.
   BMC Neurol. 2026 Feb 14. doi: 10.1186/s12883-026-04635.
   PubMed        
   
   
4. KETABI K, Haddad M, Rezayitalab F, Baghestani Z, et al
   Anti-gad autoimmune encephalitis: a case report.
   BMC Neurol. 2026 Feb 9. doi: 10.1186/s12883-026-04715.
   PubMed        
   
   
5. WAGNER JN, Moser T, Gruber J, Mylonaki E, et al
   Characteristics of and risk factors for epilepsy after autoimmune and infectious encephalitis.
   BMC Neurol. 2026 Feb 7. doi: 10.1186/s12883-026-04680.
   PubMed        
   
   

   
   Brain

6. SGODZAI M, Kloster K, Karakaya H, Didhevar P, et al
   Tipping the balance: the PD1-axis as modulator in chronic inflammatory demyelinating polyneuropathy.
   Brain. 2025 Aug 16:awaf304. doi: 10.1093.
   PubMed         Abstract available
   
   
7. ROLLOT F, Casey R, Kerbrat A, Edan G, et al
   Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.
   Brain. 2026 Feb 14:awag060. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Curr Opin Immunol

8. ALTINTAS A, Bulus E
   Multiple sclerosis: a disease or a syndrome?
   Curr Opin Immunol. 2026;99:102736.
   PubMed         Abstract available
   
   

   
   Diabet Med

9. YEU RQ, Morrow PL, Braatvedt GD
   Community deaths from diabetic ketoacidosis: A 14-year retrospective study in Auckland, New Zealand.
   Diabet Med. 2025 Dec 21:e70198. doi: 10.1111/dme.70198.
   PubMed         Abstract available
   
   
10. MEI X, Li B, Sun L, Tian Y, et al
    Druggable targets and immunological mechanisms for type 1 diabetes treatment: Genetic evidence from multi-omics Mendelian randomization combined with meta-analysis.
    Diabet Med. 2025 Dec 21:e70176. doi: 10.1111/dme.70176.
    PubMed         Abstract available
    
    
11. HEIL L, Shipman J, Smalls L, Feo R, et al
    Experiences of young people with type 1 diabetes who have transitioned from paediatric to adult care: A systematic review.
    Diabet Med. 2025 Dec 29:e70188. doi: 10.1111/dme.70188.
    PubMed         Abstract available
    
    
12. MICHAELS VR, Crocket HR, Boucsein A, Zhou Y, et al
    Experiences with Simplera sync all-in-one sensors and extended wear infusion sets in adolescents and young adults using the MiniMed 780G: A qualitative study.
    Diabet Med. 2026;43:e70197.
    PubMed         Abstract available
    
    
13. CIGLER M, Soholm U, Broadley M, Pouwer F, et al
    User evaluation of the Hypo-METRICS app: A tool for real-time symptom reporting of hypoglycaemia.
    Diabet Med. 2026;43:e70185.
    PubMed         Abstract available
    
    
14. SOHOLM U, Thuraisingam S, Holmes-Truscott E, de Zoysa N, et al
    Changes in HbA1c and diabetes-specific quality of life following structured type 1 diabetes education: Exploratory latent profile analysis of outcomes in the DAFNEplus trial.
    Diabet Med. 2026 Jan 8:e70203. doi: 10.1111/dme.70203.
    PubMed         Abstract available
    
    
15. SIDKI AS, Highton PJ, O'Mahoney LL, Wilkinson TJ, et al
    Hybrid closed-loop insulin delivery improves glycaemic control compared with sensor-augmented pump therapy: A meta-analysis of 'free-living' randomised trials in type 1 diabetes.
    Diabet Med. 2026 Jan 13:e70210. doi: 10.1111/dme.70210.
    PubMed         Abstract available
    
    
16. TILDEN DR, Bergner E, Anifowoshe K, Garretson S, et al
    Qualitative care experiences of emerging adults with type 1 diabetes after transfer to adult care providers.
    Diabet Med. 2026 Jan 13:e70214. doi: 10.1111/dme.70214.
    PubMed         Abstract available
    
    
17. ROBERTS CM, Carreon SA, Minard CG, Lyons SK, et al
    Lean on me: Social factors and diabetes outcomes among young adults with type 1 diabetes prior to transitioning to adult care.
    Diabet Med. 2026 Jan 18:e70205. doi: 10.1111/dme.70205.
    PubMed         Abstract available
    
    
18. KIM S, Park S, Jin SM, Kim JH, et al
    Association of perceived diabetes stigma with time below range <3.0 mmol/L and anxiety in adults with type 1 diabetes using continuous glucose monitoring.
    Diabet Med. 2026 Jan 18:e70204. doi: 10.1111/dme.70204.
    PubMed         Abstract available
    
    
19. STRAKOSCH T, Forbes S
    A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell-derived islets for the treatment of type 1 diabetes.
    Diabet Med. 2026 Jan 20:e70230. doi: 10.1111/dme.70230.
    PubMed         Abstract available
    
    
20. MCCARTHY A, Thomas J, Avila E, Koutroukas V, et al
    Associations between impaired awareness of hypoglycaemia and mental health in insulin-treated type 2 and type 1 diabetes in the Hypo-METRICS study.
    Diabet Med. 2026 Jan 23:e70194. doi: 10.1111/dme.70194.
    PubMed         Abstract available
    
    

    
    Diabetes

21. DELGADO-CORRALES B, Fingerhut L, Leung P, Yau CSA, et al
    Distinct Enterovirus Antigen Landscape in Children With Islet Autoimmunity.
    Diabetes. 2026 Feb 9:db250805. doi: 10.2337/db25-0805.
    PubMed         Abstract available
    
    

    
    Intern Med

22. SAKANE N, Kato K, Hata S, Nishimura E, et al
    Comparing the Validity of Three Methods for Identifying Impaired Awareness of Hypoglycemia in Predicting Severe Hypoglycemia in Adults with Type 1 Diabetes Mellitus: The PR-IAH Study.
    Intern Med. 2026;65:526-533.
    PubMed         Abstract available
    
    
23. TSUJIHATA T, Miyake H, Iwai-Kanai E, Sumiyoshi S, et al
    Microscopic Polyangiitis Initially Suspected of Being Anti-synthetase Syndrome.
    Intern Med. 2026;65:601-605.
    PubMed         Abstract available
    
    
24. ARATAKE Y, Mori H, Okada N, Akaike Y, et al
    Extraparenchymal Brain Lesions in Anti-NMDAR Encephalitis Leading to Primary Leptomeningeal Lymphoma: A Rare Evolution with Diagnostic Implications.
    Intern Med. 2026;65:587-590.
    PubMed         Abstract available
    
    
25. ORIGUCHI A, Ota Y, Kurushima S, Horai Y, et al
    Development of Nephritis and Abnormal Lung Shadow in a Patient with IgG4-related Hypertrophic Pachymeningitis with MPO-ANCA Positivity after Unplanned Interruption of Maintenance Glucocorticoid Therapy.
    Intern Med. 2026;65:606-614.
    PubMed         Abstract available
    
    

    
    J Autoimmun

26. VERONI C, Carbone F, Ricci D, Proietti S, et al
    Multiple sclerosis-associated EBNA2 variants influence the response to peginterferon beta-1a therapy.
    J Autoimmun. 2026;159:103533.
    PubMed         Abstract available
    
    

    
    J Clin Endocrinol Metab

27. FORBES S, Loo M, Tee SA, Stewart K, et al
    Cigarette Smoking Exposure and Clinical Outcomes in Graves' Disease.
    J Clin Endocrinol Metab. 2026 Feb 12:dgag061. doi: 10.1210.
    PubMed         Abstract available
    
    
28. KUCUKA I, Wolff ASB, Breivik L, Sjogren T, et al
    Long-term follow-up of autoimmune polyendocrine syndrome type-1 in Norway.
    J Clin Endocrinol Metab. 2026 Feb 12:dgag060. doi: 10.1210.
    PubMed         Abstract available
    
    

    
    J Neuroimmunol

29. ALFONSO-CEDENO DF, Medina-Lozano L, Gaete PV, Quintero-Cusguen P, et al
    Bilateral optic neuritis preceding a Balo concentric sclerosis lesion: A case report and literature review.
    J Neuroimmunol. 2026;413:578874.
    PubMed         Abstract available
    
    
30. LIU L, Lu D, Que W, Fan R, et al
    Docosahexaenoic acid supplementation aggravates myasthenia gravis through immune dysregulation.
    J Neuroimmunol. 2026;414:578889.
    PubMed         Abstract available
    
    
31. NAKASHIMA S, Sakuishi K, Hara M, Kawasaki R, et al
    Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome.
    J Neuroimmunol. 2026;414:578885.
    PubMed         Abstract available
    
    
32. YASUDA M, Uzawa A, Ogaya E, Handa H, et al
    Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis.
    J Neuroimmunol. 2026;414:578876.
    PubMed         Abstract available
    
    

    
    J Neurol

33. QU B, Li S, Chen H, Zhang Y, et al
    Disrupted and reorganized connectivity of brain networks in multiple sclerosis: a systematic review and meta-analysis of resting-state functional MRI.
    J Neurol. 2026;273:139.
    PubMed         Abstract available
    
    
34. VAN DEN BOOGAARD LJM, Bochman A, Drenthen GS, Knippenberg SAM, et al
    Longitudinal myelin MR imaging in patients with multiple sclerosis: a narrative review.
    J Neurol. 2026;273:136.
    PubMed         Abstract available
    
    
35. LIN PH, Zhang SF, Yao HY, Lai WD, et al
    Neuronal antibody targeting metabotropic glutamate receptor 8 in five cases and its pathogenicity.
    J Neurol. 2026;273:134.
    PubMed         Abstract available
    
    
36. CORSTEN CEA, Geraedts VSA, Marques AM, Melief MJ, et al
    Serum neurofilament light chain and glial fibrillary acidic protein predicting multiple sclerosis after clinically isolated syndrome.
    J Neurol. 2026;273:128.
    PubMed         Abstract available
    
    
37. FREEDMAN DE, Oh J, Feinstein A
    Relationship status and the neurobehavioral symptoms of multiple sclerosis: a cross-sectional analysis.
    J Neurol. 2026;273:126.
    PubMed         Abstract available
    
    
38. LIN L, Fang L, Huang Y, Luo Q, et al
    Brain imaging reveals hierarchical topology changes and stage-dependent impairments in autoimmune encephalitis.
    J Neurol. 2026;273:125.
    PubMed         Abstract available
    
    
39. GERNERT JA, Zausinger H, Diedrich L, Wicklein R, et al
    The potential of optical coherence tomography angiography in progressive multiple sclerosis.
    J Neurol. 2026;273:118.
    PubMed         Abstract available
    
    
40. GUO J, Olsson T, Alfredsson L, Hedstrom AK, et al
    Patient-reported gradual worsening reveals progression beyond MS subtypes.
    J Neurol. 2026;273:117.
    PubMed         Abstract available
    
    

    
    J Rheumatol

41. SINGH A, Gamboa-Cardenas RV, Pimentel-Quiroz VR, Rodriguez-Bellido Z, et al
    Association of Daily Glucocorticoid Dose With Worse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Data From the Almenara Lupus Cohort.
    J Rheumatol. 2026 Feb 15:jrheum.2025-0394. doi: 10.3899/jrheum.2025-0394.
    PubMed         Abstract available
    
    
42. RONDLA M, Zaazouee MS, Perumangote Vasudevan AA, Mathialagan K, et al
    Gut Microbiota as a Biomarker and Target in Biologic Therapy for Autoimmune and Immune-Mediated Arthritis- a Systematic Review.
    J Rheumatol. 2026 Feb 15:jrheum.2025-0915. doi: 10.3899/jrheum.2025-0915.
    PubMed         Abstract available
    
    
43. MANZI S
    Trends in Acute Coronary Syndromes in Systemic Lupus Erythematosus: Are We Moving in the Right Direction?
    J Rheumatol. 2026 Feb 15:jrheum.2026-0067. doi: 10.3899/jrheum.2026-0067.
    PubMed        
    
    

    
    Lancet

44. GROARKE EM, Turturice B, Patel BA, Quinn KA, et al
    VEXAS syndrome: a comprehensive review of pathogenesis, clinical spectrum, and therapeutic strategies.
    Lancet. 2026;407:637-648.
    PubMed         Abstract available
    
    

    
    Mult Scler

45. SHALASH A, Gams Massi D, Ben Sassi S, Tibar H, et al
    Availability and affordability of therapies and services of multiple sclerosis in Africa: A continent-wide survey.
    Mult Scler. 2026 Feb 12:13524585261417591. doi: 10.1177/13524585261417591.
    PubMed         Abstract available
    
    
46. SANGHA KS, Jakubecz C, Maynard M, Hernandez RS, et al
    Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.
    Mult Scler. 2026 Feb 9:13524585251412125. doi: 10.1177/13524585251412125.
    PubMed         Abstract available
    
    

    
    N Engl J Med

47. TONELLI M
    Targeting the Pathogenesis of IgA Nephropathy - A New Treatment Approach?
    N Engl J Med. 2026;394:712-713.
    PubMed        
    
    

    
    Neurology

48. BROWNLEE WJ, Maccarrone D, Nistri R, Yam C, et al
    Performance of the 2024 McDonald Criteria in Patients Under Evaluation for Suspected Multiple Sclerosis.
    Neurology. 2026;106:e214688.
    PubMed         Abstract available
    
    
49. ZHANG H, Janszky I, Arkema EV, Wang H, et al
    Autoimmune Diseases and Incident Spontaneous Subarachnoid Hemorrhage: A Swedish Population-Based Cohort Study.
    Neurology. 2026;106:e214679.
    PubMed         Abstract available
    
    
50. MILLER AE
    The 2024 McDonald Criteria for Diagnosis of Multiple Sclerosis: The Rubber Meets the Road.
    Neurology. 2026;106:e214688.
    PubMed        
    
    

    
    PLoS One

51. YANG B, Molton I, Humbert A, Baylor C, et al
    Environmental influences on community participation among people with multiple sclerosis: A mixed methods study.
    PLoS One. 2026;21:e0342678.
    PubMed         Abstract available
    
    
52. MUSTERER S, Vogel M, Kiess W, Richter S, et al
    Cardiac markers in children and adolescents at the onset of type 1 diabetes mellitus.
    PLoS One. 2026;21:e0342397.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

53. CUI T, Wen Q, An Z, Kang J, et al
    Natalizumab exacerbates astrocytopathy in NMOSD via blockade of endothelial VCAM1-astrocytic integrin alpha4 interaction.
    Proc Natl Acad Sci U S A. 2026;123:e2520566123.
    PubMed         Abstract available
    
    
54. LIAN L, Jang B, Huayamares SG, Shakked A, et al
    Lipid nanoparticle GM-CSF replacement for autoimmune pulmonary alveolar proteinosis.
    Proc Natl Acad Sci U S A. 2026;123:e2511483123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum